Snapshot from Sep 11, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech medical conference

Kane Biotech revyve presented at MHSRS

Analysis based on 7 articles · First reported Aug 25, 2026 · Last updated Aug 25, 2026

Sentiment
10
Attention
1
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The announcement is a positive development for Kane Biotech, potentially expanding its market into military and government healthcare channels. However, the stock closed at $0.03 without movement, indicating limited immediate market reaction.

Medical Devices Biotechnology Military Medicine

Kane Biotech Inc. announced that research on its revyve antimicrobial wound care technology was presented at the Military Health System Research Symposium (MHSRS) held August 3-5, 2026 in Kissimmee, Florida. The presentation, authored by Kane Biotech's Drs. Huizinga, Sailer and Visvalingam, was presented by Lt. Col. Steven Jeffery, a consultant plastic surgeon and professor at Birmingham City University. The presentation focused on the potential application of revyve Antimicrobial Wound Gel Spray in military and prolonged field care settings, particularly in austere environments. Following the presentation, several researchers approached Kane to explore potential applications, and Kane is working with them to develop a clinical research plan. Kane continues to advance commercialization of its revyve portfolio, which includes FDA 510(k) cleared and Canada — Health Canada approved products. The company believes military and government healthcare channels may represent a long-term opportunity.

50 Kane Biotech received interest
stock
Kane Biotech is the central entity, presenting its revyve technology at MHSRS and receiving interest from researchers. This could lead to new clinical research and potential military applications, positively impacting its commercial prospects.
Importance 100.0 Sentiment 20.0
per
Lt. Col. Steven Jeffery presented the research and endorsed the technology, lending credibility and potentially facilitating military adoption.
Importance 60.0 Sentiment 0.0
per
Dr. Robert Huizinga, Interim CEO, commented on the interest generated, representing the company's leadership in this development.
Importance 40.0 Sentiment 0.0
govactor
The FDA granted 510(k) clearance for revyve products, which is part of the regulatory background but not directly affected by this event.
Importance 30.0 Sentiment 0.0
govactor
Canada — Health Canada approved revyve products, which is part of the regulatory background but not directly affected by this event.
Importance 30.0 Sentiment 0.0
oth
Birmingham City University is the affiliation of the presenter, adding academic credibility to the presentation.
Importance 20.0 Sentiment 0.0
exch
TSX Venture Exchange is the listing exchange for Kane Biotech, and the stock price remained unchanged, indicating no immediate market reaction.
Importance 20.0 Sentiment 0.0
cnt
Ukraine is mentioned as a location where Steven Jeffery works as a burn surgeon, but it is not directly involved in the event.
Importance 10.0 Sentiment 0.0
govactor
NICE is mentioned as an organization where Steven Jeffery is an expert adviser, but it is not directly involved in the event.
Importance 10.0 Sentiment 0.0
ngo
Woundcare 4 Heroes is a charity co-founded by Steven Jeffery, but it is not directly impacted by this event.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.